Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Coiffier

Showing results (171-180 of 249) with videos related to

Pageof 25
Sort By:
The New England Journal of Medicine|January 25, 2002
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaBertrand Coiffier, Eric Lepage, Josette Briere, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programsCaroline Besson, Danielle Canioni, Eric Lepage, et al.
Journal of Hematology & Oncology|June 12, 2012
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphomaAdrien Chauchet, Anne-Sophie Michallet, Françoise Berger, et al.
Blood|October 25, 2003
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patientsMarc André, Nicolas Mounier, Xavier Leleu, et al.
Blood|April 27, 2011
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphomaRené-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter studyMiklos Pless, Karim Belhadj, Hans D Menssen, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Blood|February 11, 2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Nicolas Mounier, Josette Briere, Christian Gisselbrecht, et al.
Blood|July 20, 2017
A MALT lymphoma prognostic indexCatherine Thieblemont, Luciano Cascione, Annarita Conconi, et al.
Blood|June 16, 2010
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, et al.
Pageof 25

Showing results (171-180 of 249) with videos related to

Sort By:
Pageof 25
The New England Journal of Medicine|January 25, 2002
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaBertrand Coiffier, Eric Lepage, Josette Briere, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programsCaroline Besson, Danielle Canioni, Eric Lepage, et al.
Journal of Hematology & Oncology|June 12, 2012
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphomaAdrien Chauchet, Anne-Sophie Michallet, Françoise Berger, et al.
Blood|October 25, 2003
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patientsMarc André, Nicolas Mounier, Xavier Leleu, et al.
Blood|April 27, 2011
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphomaRené-Olivier Casasnovas, Michel Meignan, Alina Berriolo-Riedinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter studyMiklos Pless, Karim Belhadj, Hans D Menssen, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL studyFrancine Foss, Steven M Horwitz, Bertrand Coiffier, et al.
Blood|February 11, 2003
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Nicolas Mounier, Josette Briere, Christian Gisselbrecht, et al.
Blood|July 20, 2017
A MALT lymphoma prognostic indexCatherine Thieblemont, Luciano Cascione, Annarita Conconi, et al.
Blood|June 16, 2010
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, et al.
Pageof 25